India has partially revoked another Big Pharma patent -- this time Roche's Herceptin -- apparently in an effort to stem the drug's price ($1400 per month) in the market and improve its accessibility to patients. It appears that Indian officials are trying to negate any connection that is being made between the latest decision and perceived expensive pricing for the drug in question.
Let's total the score now. India has now disallowed patents or granted a compulsory license for Bayer's Nexavar, Novartis' Gleevec, GSK's Tykerb and Roche's Herceptin. Any wonder that pharma companies and the US government have been increasingly vocal about the Indian Governments apparent disregard for intellectual property rights?
Pharma is no doubt frightened that this will continue in India and that this trend may spread to other countries in the region. It also may call into question and Big Pharma strategy tha exists for making up sales losses in the US or EU due to patent cliff issues by selling more product in the less developed regions of thw world. These latter countries may not turn out to be fertile pickings -- and actually may make things worse if IP starts disappearing. See Pharmalot.
Posted by Bruce Lehr Aug 6th 2013.